Calcitriol ointment: A review of a topical vitamin D analog for psoriasis

References

• Rizova E, Corroller M. Topical calcitriol - Studies on local tolerance and systemic safety. Br J Dermatol. 2001; 144( (suppl 58))3–10
   Google Scholar
• Barker JN, Berth-jones J, Groves R, Omerod AD, Rizova E, Griffiths CE. Calcium homeostasis remains unaffected after 12 weeks’ therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis. J Dermatolog Treat. 2003; 14: 14–21
   PubMedGoogle Scholar
• Carboni I, de Felice C, Bergamin A, Chimenti S. Topical use of calcitriol 3 microg/g ointment in the treatment of mild- to-moderate psoriasis: Results from an open-label study. J Eur Acad Dermatol Venereol. 2005;; 19((suppl 3))11–13
   Google Scholar
• Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol. 2007; 21: 466–72
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: Results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2007; 6: 428–35
   PubMedGoogle Scholar
• Ortonne JP, Humbert P, Nicolas JF, Tsankov N, Tonev SD, Janin A, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003; 148: 326––33
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PCM. Psoriasis. Dermatology., J Bolognia, J Jorizzo, R Rapini. Mosby, London, New York 2003; 127–138
   Google Scholar
• Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: A cell biological study. Br J Dermatol. 1993; 128: 666–73
   PubMedGoogle Scholar
• Gorman S, Kuritzky LA, Judge MA, Dixon KM, Mcglade JP, Mason RS, et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol. 2007; 179: 6273–83
   PubMed Web of Science ®Google Scholar
• Langner A, Ashton p, Van de Kerlhof PC, Verjans H. A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol. 1996; 135: 385–9
   PubMed Web of Science ®Google Scholar
• Queille-roussel C, Duteil L, Parneix-spake A, Arsonnaud S, Rizova E. The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity. Eur J Dermatol. 2001; 11: 219–24
   PubMed Web of Science ®Google Scholar
• Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008; 9: 345–59
   PubMedGoogle Scholar
• Gargoom AM, Duweb GA, Elzorghany AH, Benghazil M, Bugrein OO. Calcipotriol in the treatment of childhood vitiligo. Int J Clin Pharmacol Res. 2004; 24: 11–4
   PubMedGoogle Scholar
• Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol. 2001; 145: 472–5
   PubMedGoogle Scholar
• Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol. 2001; 145: 476–9
   PubMedGoogle Scholar
• Emtestam L, Weden U. Successful treatment for acrodermatitis continua of Hallopeau using topical calcipotriol. Br J Dermatol. 1996; 135: 644–6
   Google Scholar
• Rajpara SM, King CM. Hailey-Hailey disease responsive to topical calcitriol. Br J Dermatol. 2005; 152: 816–17
   PubMedGoogle Scholar
• Urbina F, Misad C, Gonzalez S. Circumscribed palmar hypokeratosis: Clinical evolution and ultrastructural study after prolonged treatment with topical calcipotriol. J Eur Acad Dermatol Venereol. 2005; 19: 491–4
   Google Scholar
• Godic A, Dragos V. Successful treatment of Netherton's syndrome with topical calcipotriol. Eur J Dermatol. 2004; 14: 115–17
   PubMed Web of Science ®Google Scholar
• Gupta S, Saraswat A, Kumar B. Treatment of genital lichen sclerosus with topical calcipotriol. Int J STD AIDS. 2005; 16: 772–4
   Google Scholar
• Imagawa I, Suzuki H. Successful treatment of refractory warts with topical vitamin D3 derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol. 2007; 34: 264–6
   PubMed Web of Science ®Google Scholar
• Mota AV, Correia TM, Lopes JM, Guimaraes JM. Successful treatment of Grover's disease with calcipotriol. Eur J Dermatol. 1998; 8: 33–5
   Google Scholar
• Tay YK. Topical calcipotriol ointment in the treatment of morphea. J Dermatolog Treat. 2003; 14: 219–21
   PubMedGoogle Scholar
• Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998; 39: 211–15
   PubMed Web of Science ®Google Scholar
• Bayramgurler D, Apaydin R, Bilen N. Limited benefit of topical calcipotriol in lichen planus treatment: A preliminary study. J Dermatolog Treat. 2002; 13: 129–32
   PubMed Web of Science ®Google Scholar